467 related articles for article (PubMed ID: 25456951)
1. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
[TBL] [Abstract][Full Text] [Related]
2. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas.
Kouvaraki MA; Liakou C; Paraschi A; Dimas K; Patsouris E; Tseleni-Balafouta S; Rassidakis GZ; Moraitis D
Surgery; 2011 Dec; 150(6):1258-65. PubMed ID: 22136849
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
4. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
5. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.
Jacinto E; Facchinetti V; Liu D; Soto N; Wei S; Jung SY; Huang Q; Qin J; Su B
Cell; 2006 Oct; 127(1):125-37. PubMed ID: 16962653
[TBL] [Abstract][Full Text] [Related]
6. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
7. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
8. AKT activity is elevated in aggressive thyroid neoplasms where it promotes proliferation and invasion.
Matson DR; Hardin H; Buehler D; Lloyd RV
Exp Mol Pathol; 2017 Dec; 103(3):288-293. PubMed ID: 29169802
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.
Rosner M; Hengstschläger M
Hum Mol Genet; 2008 Oct; 17(19):2934-48. PubMed ID: 18614546
[TBL] [Abstract][Full Text] [Related]
10. Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants.
Liu J; Brown RE
Mod Pathol; 2011 Dec; 24(12):1553-9. PubMed ID: 21822208
[TBL] [Abstract][Full Text] [Related]
11. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
12. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells.
Das G; Shiras A; Shanmuganandam K; Shastry P
Mol Carcinog; 2011 Jun; 50(6):412-23. PubMed ID: 21557327
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin regulates the phosphorylation of rictor.
Akcakanat A; Singh G; Hung MC; Meric-Bernstam F
Biochem Biophys Res Commun; 2007 Oct; 362(2):330-3. PubMed ID: 17707343
[TBL] [Abstract][Full Text] [Related]
14. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
15. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.
Liu P; Gan W; Chin YR; Ogura K; Guo J; Zhang J; Wang B; Blenis J; Cantley LC; Toker A; Su B; Wei W
Cancer Discov; 2015 Nov; 5(11):1194-209. PubMed ID: 26293922
[TBL] [Abstract][Full Text] [Related]
16. Gene expression in poorly differentiated papillary thyroid carcinomas.
Fluge Ø; Bruland O; Akslen LA; Lillehaug JR; Varhaug JE
Thyroid; 2006 Feb; 16(2):161-75. PubMed ID: 16676402
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W.
Jeon YH; Park YH; Kwon JH; Lee JH; Kim IY
Biochim Biophys Acta; 2013 Oct; 1833(10):2135-42. PubMed ID: 23680186
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
19. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.
Yin Y; Hua H; Li M; Liu S; Kong Q; Shao T; Wang J; Luo Y; Wang Q; Luo T; Jiang Y
Cell Res; 2016 Jan; 26(1):46-65. PubMed ID: 26584640
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
